Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

The Signal Transducer and Activator of Transcription 3 (STAT3) oncogene is a master regulator of many human cancers, and a well-recognized target for therapeutic intervention. A well known STAT3 inhibitor, S3I-201 (NSC 74859), is hypothesized to block STAT3 function in cancer cells by binding the STAT3 SH2 domain and disrupt STAT3 protein complexation events. In this study, liquid chromatography tandem mass spectrometry analysis revealed that STAT3, in the presence of S3I-201, showed a minimum of five specific sites of modification, cysteine's 108, 259, 367, 542, and 687. Moreover, a prepared fluorescently labeled chemical probe of S3I-201 (DB-6-055) revealed that S3I-201 non-specifically and globally alkylated intracellular proteins at concentrations consistent with S3I-201's reported IC50. These data are consistent with the hypothesis that S3I-201 is a sub-optimal probe for interrogating STAT3-related cell biology.

Original publication

DOI

10.18632/oncotarget.7838

Type

Journal article

Journal

Oncotarget

Publication Date

12/04/2016

Volume

7

Pages

20669 - 20679

Keywords

NSC 74859, S3I-201, STAT3, covalent modification, oncology, Alkylating Agents, Aminosalicylic Acids, Apoptosis, Benzenesulfonates, Breast Neoplasms, Cell Proliferation, Female, Humans, STAT3 Transcription Factor, Tumor Cells, Cultured